RAF1 mutation

Rigosertib: A Promising Therapeutic Agent for Reversing Hypertrophic Cardiomyopathy in Noonan Syndrome

Rigosertib demonstrates significant reversal of hypertrophic cardiomyopathy and other syndromic features in Noonan syndrome models, highlighting its potential as a targeted therapy for RASopathy-associated cardiac and developmental abnormal